Igenomix portfolio includes pioneering genetic tests to help reproductive-health professionals to analyse and treat their patients before, during and after their reproductive journey.
Our Brands
Vitrolife delivers innovative, high-quality products to ensure optimal care at every stage of the IVF journey, from error prevention and gamete handling to embryo evaluation and cryopreservation.
Annual Report
Vitrolife Group Annual and Sustainability Report for 2025
We are pleased to announce the release of Vitrolife Group’s Annual Report for 2025.
Despite a volatile market, we delivered a resilient performance, continued to gain market share in key regions, and maintained our strategic focus on growth, innovation, and operational excellence.
Latest financial report
Interim report Q3: Improved growth driven by Technologies
In terms of overall market conditions during the quarter, we saw a pickup in cycles in Europe. Americas continues to show solid growth, and APAC is a mixed picture with China cycles down versus last year, however other major markets in APAC are trending positively.
Press Releases
22 October 2026
Interim report Q3, 2026: Improved growth driven by Technologies
07 October 2026
Invitation to Vitrolife Group's presentation of the Q3 2026 interim report
13 August 2026
Financial Calendar
-
28 Jan 2027
Fourth quarter and full year report 2026
-
25 Mar 2027
Annual and sustainability report 2026
-
22 Apr 2027
Interim report Q1, 2027
Careers
The Vitrolife Group offers an attractive workplace with an opportunity to work for a higher purpose, a purpose that makes a difference in people’s lives worldwide.
Investor relations
Our aim is to have a strong capital base to enable continued high growth, both organically and through acquisitions. We strive to achieve growth through profitability.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.